Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case

ABSTRACT Myelodysplastic syndrome with deletion of chromosome 5q (5q-syndrome) has a favorable prognosis and a low risk of transformation to acute myeloid leukemia, when treated with lenalidomide. Azacitidine leads to complete remission even as second-line therapy and in patients with clonal evoluti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Palacios-Campos,Adriana, Gutierrez,Olga, Fabian-Morales,Eunice, Avilés,Alejandro, Candelaria,Myrna
Lenguaje:	English
Publicado:	Sociedad Médica de Santiago 2020
Materias:	Azacitidine Lenalidomide Myelodysplastic Syndromes
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000901357
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872020000901357
record_format	dspace
spelling	oai:scielo:S0034-988720200009013572020-12-26Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one casePalacios-Campos,AdrianaGutierrez,OlgaFabian-Morales,EuniceAvilés,AlejandroCandelaria,Myrna Azacitidine Lenalidomide Myelodysplastic Syndromes ABSTRACT Myelodysplastic syndrome with deletion of chromosome 5q (5q-syndrome) has a favorable prognosis and a low risk of transformation to acute myeloid leukemia, when treated with lenalidomide. Azacitidine leads to complete remission even as second-line therapy and in patients with clonal evolution. We report a 70 years old female without previous exposure to myelotoxic drugs, presenting with three weeks with fatigue and dyspnea. She had anemia with normal white blood cell and platelet count. Bone marrow biopsy showed 50% cellularity and the karyotype analysis revealed a (5) (q33q34) deletion in 22% of the metaphases. A diagnosis of 5q-syndrome with low risk calculated using the Revised International Prognostic Scoring System (IPSS-R), was made. Since lenalidomide was not affordable, thalidomide 100 mg/day was initiated, achieving transfusion independence for three years. Afterwards, she developed pancytopenia and a bone marrow biopsy showed erythroid and megakaryocyte dysplasia with a complex karyotype, which worsened prognosis (IPSS-R of five points). Therefore, azacitidine (by donation) was administered. She achieved complete remission with a normal karyotype and completed 12 cycles of treatment. Thereafter, she relapsed and received only supportive care for a year. She suffered an ischemic stroke and died two weeks later.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.148 n.9 20202020-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000901357en10.4067/S0034-98872020000901357
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Azacitidine Lenalidomide Myelodysplastic Syndromes
spellingShingle	Azacitidine Lenalidomide Myelodysplastic Syndromes Palacios-Campos,Adriana Gutierrez,Olga Fabian-Morales,Eunice Avilés,Alejandro Candelaria,Myrna Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
description	ABSTRACT Myelodysplastic syndrome with deletion of chromosome 5q (5q-syndrome) has a favorable prognosis and a low risk of transformation to acute myeloid leukemia, when treated with lenalidomide. Azacitidine leads to complete remission even as second-line therapy and in patients with clonal evolution. We report a 70 years old female without previous exposure to myelotoxic drugs, presenting with three weeks with fatigue and dyspnea. She had anemia with normal white blood cell and platelet count. Bone marrow biopsy showed 50% cellularity and the karyotype analysis revealed a (5) (q33q34) deletion in 22% of the metaphases. A diagnosis of 5q-syndrome with low risk calculated using the Revised International Prognostic Scoring System (IPSS-R), was made. Since lenalidomide was not affordable, thalidomide 100 mg/day was initiated, achieving transfusion independence for three years. Afterwards, she developed pancytopenia and a bone marrow biopsy showed erythroid and megakaryocyte dysplasia with a complex karyotype, which worsened prognosis (IPSS-R of five points). Therefore, azacitidine (by donation) was administered. She achieved complete remission with a normal karyotype and completed 12 cycles of treatment. Thereafter, she relapsed and received only supportive care for a year. She suffered an ischemic stroke and died two weeks later.
author	Palacios-Campos,Adriana Gutierrez,Olga Fabian-Morales,Eunice Avilés,Alejandro Candelaria,Myrna
author_facet	Palacios-Campos,Adriana Gutierrez,Olga Fabian-Morales,Eunice Avilés,Alejandro Candelaria,Myrna
author_sort	Palacios-Campos,Adriana
title	Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
title_short	Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
title_full	Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
title_fullStr	Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
title_full_unstemmed	Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
title_sort	transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. report of one case
publisher	Sociedad Médica de Santiago
publishDate	2020
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000901357
work_keys_str_mv	AT palacioscamposadriana transitoryresponseofamyelodysplasticsyndromewithdeletionofchromosome5qtothalidomidereportofonecase AT gutierrezolga transitoryresponseofamyelodysplasticsyndromewithdeletionofchromosome5qtothalidomidereportofonecase AT fabianmoraleseunice transitoryresponseofamyelodysplasticsyndromewithdeletionofchromosome5qtothalidomidereportofonecase AT avilesalejandro transitoryresponseofamyelodysplasticsyndromewithdeletionofchromosome5qtothalidomidereportofonecase AT candelariamyrna transitoryresponseofamyelodysplasticsyndromewithdeletionofchromosome5qtothalidomidereportofonecase
_version_	1718437153530183680

Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case

Ejemplares similares